CagriSema CagriSema is an investigational fixed-dose combination of cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist, co-administered once weekly and studied in Phase 3 trials for obesity and type 2 diabetes.
These peptides may have also helped improve these subjects cholesterol profiles and glucose tolerance levels
Consequently, the definition of treatment success is also expanding beyond headline weight loss achieved, to include the full spectrum of patients therapeutic needs, for example: Effective and durable weight maintenance Managing co-morbidities along the cardio-metabolic-renal spectrum Preserving muscle mass Tolerability, safety Convenience, e.g., delivered via oral therapies and/or less-frequent dosing * Including diabetes, ASCVD, Afib, HTN, PAH, dyslipidaemia, heart failure, PAD, MI, stroke, cardiovascular disease, CKD Source: IQVIA LAAD
The mechanism is well mapped
Explain the expected side effects, what is known/unproven, and potential long-term implications
& Kaddoumi, A